In light of reports suggesting that the intrinsic type of AD is characterized by the domination of Th17 and Th9 lymphocytes with domination of the corresponding cytokine profile (IL-17, IL-12/IL23p40, IL-9) [84], suggestion of the Th17/Th22 endotype dependent on skin apparently unchanged in AZS [8], and ethnic differences indicating that the lymphocytic-cytokine profile in Asians with AD patients outside Th2 includes Th17, it seems that the subgroup of AD patients characterized by low levels of IgE and increased activation of Th17 can successfully respond to anti-IL17 therapy [84]. The gene discussed is IL17A; the disease is Alzheimer disease.